Damora Therapeutics Inc (DMRA) 13F Holders & Ownership Data (103 Funds, Q2 2026)

DMRA ranks #4533 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

DMRA is a top-conviction position for Fairmount Funds Management LLC — at 15.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in DMRA belongs to FMR LLC, but the position matters far more to Fairmount Funds Management LLC, who has 15.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its DMRA position for two straight quarters, increasing it by $234.7M to reach $240.1M today.

DMRA is down 1.6% today, but institutions show net buying of $285.8M this quarter — a divergence between today's price move and the underlying institutional flow.

DMRA reported a net loss of $209.8M in its latest fiscal year.

• Not yet profitable — net loss of $209.8M in the latest fiscal year
• Net income declined year over year, from -$21.4M to -$209.8M
• Operating cash flow was negative, using $6.7M in cash
• Current ratio of 12.98x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.08x equity — within a conventional range